Galmed Pharmaceuticals (GLMD) Operating Leases (2019 - 2022)

Galmed Pharmaceuticals' Operating Leases history runs 4 years deep, the most recent figure standing at $44000.0 for Q4 2022.

• In Q4 2022, Operating Leases fell 89.89% year-over-year to $44000.0; the TTM figure through Dec 2022 stood at $44000.0 (down 89.89% YoY), while the FY2022 annual figure was $44000.0, down 89.89% from the prior year.
• Operating Leases was $44000.0 for Q4 2022 at Galmed Pharmaceuticals, down from $89000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $216.0 million in Q4 2020 to a low of $44000.0 in Q4 2022.
• Historically, Operating Leases has averaged $13.8 million across 4 years, with a median of $292500.0 in 2020.
• The sharpest annual moves came in 2020 and 2021: Operating Leases surged 61263.64% in 2020, then sank 99.8% in 2021.
• A 4-year view of Operating Leases shows it stood at $352000.0 in 2019, then soared by 61263.64% to $216.0 million in 2020, then tumbled by 99.8% to $435000.0 in 2021, then sank by 89.89% to $44000.0 in 2022.
• The last three Operating Leases figures came in at $44000.0 (Q4 2022), $89000.0 (Q3 2022), and $134000.0 (Q2 2022), per Business Quant data.